CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.15 Billion KRW | -36.67% |
| 2022 | -14.77 Billion KRW | -50.56% |
| 2021 | -9.81 Billion KRW | -228.96% |
| 2020 | 7.6 Billion KRW | -50.64% |
| 2019 | 15.41 Billion KRW | 119.9% |
| 2018 | 7 Billion KRW | -22.4% |
| 2017 | 9.03 Billion KRW | -22.24% |
| 2016 | 11.61 Billion KRW | 44.44% |
| 2015 | 8.04 Billion KRW | 404.46% |
| 2014 | -2.64 Billion KRW | -235.56% |
| 2013 | 1.94 Billion KRW | -77.86% |
| 2012 | 8.79 Billion KRW | -35.04% |
| 2011 | 13.54 Billion KRW | -16.24% |
| 2010 | 16.17 Billion KRW | -5.38% |
| 2009 | 17.08 Billion KRW | 124.77% |
| 2008 | 7.6 Billion KRW | 1872.83% |
| 2007 | 385.4 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.18 Billion KRW | 163.72% |
| 2024 Q2 | 4.98 Billion KRW | 56.29% |
| 2024 Q3 | 2.57 Billion KRW | -48.26% |
| 2023 Q2 | -5.82 Billion KRW | -57.54% |
| 2023 Q4 | -5 Billion KRW | 12.05% |
| 2023 FY | -20.18 Billion KRW | -36.67% |
| 2023 Q1 | -3.7 Billion KRW | 62.62% |
| 2023 Q3 | -5.68 Billion KRW | 2.45% |
| 2022 Q3 | -1.14 Billion KRW | 71.45% |
| 2022 Q2 | -4.02 Billion KRW | -1252.77% |
| 2022 Q1 | -297.34 Million KRW | 92.67% |
| 2022 FY | -14.77 Billion KRW | -50.56% |
| 2022 Q4 | -9.89 Billion KRW | -761.86% |
| 2021 Q2 | -1.28 Billion KRW | 44.87% |
| 2021 Q1 | -2.32 Billion KRW | -120.61% |
| 2021 Q3 | -3.76 Billion KRW | -193.9% |
| 2021 Q4 | -4.05 Billion KRW | -7.63% |
| 2021 FY | -9.81 Billion KRW | -228.96% |
| 2020 Q1 | 3.42 Billion KRW | -23.98% |
| 2020 Q3 | 1.33 Billion KRW | -65.74% |
| 2020 Q4 | -1.05 Billion KRW | -178.91% |
| 2020 FY | 7.6 Billion KRW | -50.64% |
| 2020 Q2 | 3.9 Billion KRW | 13.87% |
| 2019 Q1 | 2.5 Billion KRW | 40.05% |
| 2019 Q3 | 4.37 Billion KRW | 8.84% |
| 2019 Q4 | 4.5 Billion KRW | 2.89% |
| 2019 FY | 15.41 Billion KRW | 119.9% |
| 2019 Q2 | 4.02 Billion KRW | 60.69% |
| 2018 Q2 | 907.52 Million KRW | -41.11% |
| 2018 Q3 | 2.77 Billion KRW | 205.5% |
| 2018 FY | 7 Billion KRW | -22.4% |
| 2018 Q1 | 1.54 Billion KRW | -8.84% |
| 2018 Q4 | 1.78 Billion KRW | -35.51% |
| 2017 Q1 | 2.03 Billion KRW | 76.85% |
| 2017 FY | 9.03 Billion KRW | -22.24% |
| 2017 Q4 | 1.69 Billion KRW | -45.65% |
| 2017 Q3 | 3.11 Billion KRW | 41.29% |
| 2017 Q2 | 2.2 Billion KRW | 8.44% |
| 2016 FY | 11.61 Billion KRW | 44.44% |
| 2016 Q4 | 1.14 Billion KRW | -54.8% |
| 2016 Q3 | 2.53 Billion KRW | -24.23% |
| 2016 Q2 | 3.35 Billion KRW | -26.75% |
| 2016 Q1 | 4.57 Billion KRW | 51.83% |
| 2015 FY | 8.04 Billion KRW | 404.46% |
| 2015 Q2 | 735.8 Million KRW | -13.85% |
| 2015 Q3 | 3.43 Billion KRW | 367.29% |
| 2015 Q1 | 854.06 Million KRW | 178.34% |
| 2015 Q4 | 3.01 Billion KRW | -12.34% |
| 2014 Q3 | -968.31 Million KRW | -206.81% |
| 2014 Q2 | -315.61 Million KRW | -18.04% |
| 2014 Q1 | -267.36 Million KRW | -229.51% |
| 2014 Q4 | -1.09 Billion KRW | -12.59% |
| 2014 FY | -2.64 Billion KRW | -235.56% |
| 2013 FY | 1.94 Billion KRW | -77.86% |
| 2013 Q2 | 214.38 Million KRW | 8.19% |
| 2013 Q3 | 1.32 Billion KRW | 520.18% |
| 2013 Q1 | 198.14 Million KRW | -18.95% |
| 2013 Q4 | 206.43 Million KRW | -84.47% |
| 2012 FY | 8.79 Billion KRW | -35.04% |
| 2012 Q4 | 244.47 Million KRW | -93.13% |
| 2012 Q3 | 3.55 Billion KRW | 26.81% |
| 2012 Q2 | 2.8 Billion KRW | 28.18% |
| 2012 Q1 | 2.18 Billion KRW | -53.08% |
| 2011 Q1 | 4.53 Billion KRW | 22.47% |
| 2011 FY | 13.54 Billion KRW | -16.24% |
| 2011 Q4 | 4.66 Billion KRW | 191.77% |
| 2011 Q3 | 1.59 Billion KRW | -41.78% |
| 2011 Q2 | 2.74 Billion KRW | -39.4% |
| 2010 Q3 | 5.52 Billion KRW | 97.9% |
| 2010 FY | 16.17 Billion KRW | -5.38% |
| 2010 Q2 | 2.79 Billion KRW | -28.04% |
| 2010 Q1 | 3.87 Billion KRW | 17.71% |
| 2010 Q4 | 3.7 Billion KRW | -32.98% |
| 2009 Q4 | 3.29 Billion KRW | -21.62% |
| 2009 FY | 17.08 Billion KRW | 124.77% |
| 2009 Q2 | 3.25 Billion KRW | -45.07% |
| 2009 Q1 | 5.93 Billion KRW | 62.94% |
| 2009 Q3 | 4.2 Billion KRW | 29.04% |
| 2008 Q3 | 1.54 Billion KRW | 20.18% |
| 2008 Q4 | 3.63 Billion KRW | 135.65% |
| 2008 Q1 | 1.13 Billion KRW | 465.21% |
| 2008 FY | 7.6 Billion KRW | 1872.83% |
| 2008 Q2 | 1.28 Billion KRW | 13.37% |
| 2007 FY | 385.4 Million KRW | 0.0% |
| 2007 Q3 | 723.2 Million KRW | 1001.93% |
| 2007 Q1 | -466.36 Million KRW | 0.0% |
| 2007 Q2 | -80.18 Million KRW | 82.81% |
| 2007 Q4 | 200.57 Million KRW | -72.27% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5628.249% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 126.212% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 74.671% |
| HANDOK Inc. | 12.57 Billion KRW | 260.21% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -913.126% |
| Yuhan Corporation | 74.56 Billion KRW | 127.028% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 280.28% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -11.695% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 108.961% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 759.428% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 240.432% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 3479.012% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 2191.019% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 174.552% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5628.249% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -159.83% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 599.613% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 71.19% |
| JW Holdings Corporation | 143.66 Billion KRW | 114.027% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 62.274% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 108.172% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 120.091% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 57.477% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 390.93% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 411.427% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 330.806% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5628.249% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 141.324% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 115.106% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 120.091% |
| Yuhan Corporation | 74.56 Billion KRW | 127.028% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 196.331% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 746.454% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 146.872% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 120.091% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 198.38% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 136.674% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 162.522% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 179.648% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 161.96% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 57.477% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 160.798% |
| Boryung Corporation | 68.26 Billion KRW | 129.52% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 46.255% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 240.432% |
| JW Lifescience Corporation | 32.09 Billion KRW | 162.797% |